GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OTCPK:AKBLF) » Definitions » E10

AKBLF (Alk-Abello AS) E10 : $0.14 (As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Alk-Abello AS E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Alk-Abello AS's adjusted earnings per share data for the three months ended in Dec. 2024 was $0.110. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.14 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Alk-Abello AS's average E10 Growth Rate was 38.90% per year. During the past 3 years, the average E10 Growth Rate was 27.70% per year. During the past 5 years, the average E10 Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Alk-Abello AS was 27.70% per year. The lowest was -51.70% per year. And the median was -1.20% per year.

As of today (2025-03-02), Alk-Abello AS's current stock price is $21.35. Alk-Abello AS's E10 for the quarter that ended in Dec. 2024 was $0.14. Alk-Abello AS's Shiller PE Ratio of today is 152.50.

During the past 13 years, the highest Shiller PE Ratio of Alk-Abello AS was 379.56. The lowest was 8.09. And the median was 169.02.


Alk-Abello AS E10 Historical Data

The historical data trend for Alk-Abello AS's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS E10 Chart

Alk-Abello AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.07 0.08 0.09 0.14

Alk-Abello AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.11 0.11 0.14 0.14

Competitive Comparison of Alk-Abello AS's E10

For the Biotechnology subindustry, Alk-Abello AS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello AS's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's Shiller PE Ratio falls into.



Alk-Abello AS E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alk-Abello AS's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.11/118.9000*118.9000
=0.110

Current CPI (Dec. 2024) = 118.9000.

Alk-Abello AS Quarterly Data

per share eps CPI Adj_EPS
201503 0.066 100.200 0.078
201506 0.038 100.300 0.045
201509 0.045 100.200 0.053
201512 0.102 99.800 0.122
201603 0.090 100.200 0.107
201606 0.053 100.600 0.063
201609 0.030 100.200 0.036
201612 0.025 100.300 0.030
201703 0.001 101.200 0.001
201706 -0.001 101.200 -0.001
201709 -0.019 101.800 -0.022
201712 -0.117 101.300 -0.137
201803 0.018 101.700 0.021
201806 -0.013 102.300 -0.015
201809 -0.019 102.400 -0.022
201812 -0.103 102.100 -0.120
201903 0.031 102.900 0.036
201906 -0.047 102.900 -0.054
201909 -0.021 102.900 -0.024
201912 -0.009 102.900 -0.010
202003 0.058 103.300 0.067
202006 -0.007 103.200 -0.008
202009 -0.014 103.500 -0.016
202012 -0.023 103.400 -0.026
202103 0.093 104.300 0.106
202106 -0.016 105.000 -0.018
202109 0.027 105.800 0.030
202112 0.052 106.600 0.058
202203 0.104 109.900 0.113
202206 0.028 113.600 0.029
202209 0.027 116.400 0.028
202212 0.044 115.900 0.045
202303 0.101 117.300 0.102
202306 0.044 116.400 0.045
202309 0.072 117.400 0.073
202312 0.088 116.700 0.090
202403 0.160 118.400 0.161
202406 0.130 118.500 0.130
202409 0.149 118.900 0.149
202412 0.110 118.900 0.110

Add all the adjusted EPS together and divide 10 will get our e10.


Alk-Abello AS  (OTCPK:AKBLF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Alk-Abello AS's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=21.35/0.14
=152.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Alk-Abello AS was 379.56. The lowest was 8.09. And the median was 169.02.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Alk-Abello AS E10 Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello AS Business Description

Traded in Other Exchanges
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Alk-Abello AS Headlines